• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生长分化因子 15 和骨保护素在急性心肌梗死并发心源性休克中的变化:IABP-SHOCK II 试验的生物标志物亚研究。

Growth-differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the IABP-SHOCK II-trial.

机构信息

Department of Internal Medicine/Cardiology, University of Leipzig-Heart Center, Leipzig, Germany.

出版信息

Eur J Heart Fail. 2014 Aug;16(8):880-7. doi: 10.1002/ejhf.117. Epub 2014 Jun 5.

DOI:10.1002/ejhf.117
PMID:24903195
Abstract

AIMS

This study investigates the role of osteoprotegerin (OPG) and growth-differentiation factor 15 (GDF-15) as predictors of outcome in cardiogenic shock (CS) complicating acute myocardial infarction. The novel biomarkers OPG and GDF-15 have shown prognostic impact in various cardiovascular diseases including myocardial infarction. In acute myocardial infarction complicated by CS, the diagnostic and prognostic impact of these biomarkers has not been investigated yet. OPG and GDF-15 may have additional prognostic impact on early prognosis assessment, being potentially useful for decision-making in CS.

METHODS AND RESULTS

In the randomized Intra-aortic Balloon Pump in cardiogenic Shock II (IABP-SHOCK II)-trial, 600 patients with CS complicating acute myocardial infarction undergoing early revascularization were assigned to therapy with or without IABP. Within a pre-defined substudy, blood samples were collected from 190 patients during PCI. GDF-15 and OPG serum levels were measured with standard enzyme-linked immunosorbent assay kits. Patients with GDF-15 and OPG levels greater than the median showed higher rates of death at 30 days by χ(2) testing (OPG, 51% vs. 32%, P = 0.01; GDF-15, 52% vs. 31%, P = 0.005) and log rank testing [GDF-15, hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.21-2.94; P = 0.005; OPG, HR 1.74, 95% CI 1.11-2.71; P = 0.01]. Both markers were significantly predictive of 30-day mortality in univariable logistic regression analysis. In a multivariable logistic stepwise regression model, GDF-15, TIMI (Thrombolysis In Myocardial Infarction) flow grade <3 after PCI, age, LVEF, and serum lactate remained significant predictors of 30-day mortality.

CONCLUSION

GDF-15 on admission is a significant independent predictor of short-term mortality in infarct-related CS. Trail registration: NCT00491036.

摘要

目的

本研究旨在探讨骨保护素(OPG)和生长分化因子 15(GDF-15)作为急性心肌梗死并发心原性休克(CS)患者预后预测因子的作用。新型生物标志物 OPG 和 GDF-15 在包括心肌梗死在内的各种心血管疾病中显示出预后影响。在急性心肌梗死并发 CS 的情况下,这些生物标志物的诊断和预后影响尚未得到研究。OPG 和 GDF-15 可能对早期预后评估具有额外的预后影响,对于 CS 的决策制定可能具有潜在的用途。

方法和结果

在随机的主动脉内球囊泵在心原性休克 II (IABP-SHOCK II)试验中,600 例急性心肌梗死并发 CS 并接受早期血运重建的患者被分为接受或不接受 IABP 治疗的两组。在一个预先确定的亚研究中,从 190 例患者在 PCI 期间采集血样。使用标准酶联免疫吸附试验试剂盒测量 GDF-15 和 OPG 血清水平。通过卡方检验(OPG,51%比 32%,P = 0.01;GDF-15,52%比 31%,P = 0.005)和对数秩检验[GDF-15,危险比(HR)1.88,95%置信区间(CI)1.21-2.94;P = 0.005;OPG,HR 1.74,95% CI 1.11-2.71;P = 0.01],具有 GDF-15 和 OPG 中位数以上水平的患者在 30 天时的死亡率更高。在单变量逻辑回归分析中,这两种标志物均是 30 天死亡率的显著预测因子。在多变量逻辑逐步回归模型中,PCI 后 TIMI(血栓溶解治疗心肌梗死)血流分级<3、年龄、LVEF 和血清乳酸是 30 天死亡率的独立显著预测因子。

结论

入院时 GDF-15 是与梗塞相关 CS 患者短期死亡率的显著独立预测因子。

试验注册

NCT00491036。

相似文献

1
Growth-differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the IABP-SHOCK II-trial.生长分化因子 15 和骨保护素在急性心肌梗死并发心源性休克中的变化:IABP-SHOCK II 试验的生物标志物亚研究。
Eur J Heart Fail. 2014 Aug;16(8):880-7. doi: 10.1002/ejhf.117. Epub 2014 Jun 5.
2
Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial.急性心肌梗死合并心源性休克时的成纤维细胞生长因子23:心源性休克主动脉内球囊反搏II(IABP-SHOCK II)试验的生物标志物子研究
Crit Care. 2014 Dec 21;18(6):713. doi: 10.1186/s13054-014-0713-8.
3
Angiopoietin-2 in acute myocardial infarction complicated by cardiogenic shock--a biomarker substudy of the IABP-SHOCK II-Trial.急性心肌梗合并心原性休克患者中血管生成素 2 的变化——IABP-SHOCK II 试验的生物标志物亚研究。
Eur J Heart Fail. 2015 Nov;17(11):1152-60. doi: 10.1002/ejhf.342. Epub 2015 Sep 3.
4
Prognostic impact of established and novel renal function biomarkers in myocardial infarction with cardiogenic shock: A biomarker substudy of the IABP-SHOCK II-trial.已确立的和新型肾功能生物标志物在心肌梗死合并心源性休克中的预后影响:IABP-SHOCK II试验的生物标志物子研究
Int J Cardiol. 2015 Jul 15;191:159-66. doi: 10.1016/j.ijcard.2015.04.242. Epub 2015 May 1.
5
Catalytic iron in acute myocardial infarction complicated by cardiogenic shock - A biomarker substudy of the IABP-SHOCK II-trial.急性心肌梗死合并心源性休克中的催化铁——IABP-SHOCK II试验的生物标志物子研究
Int J Cardiol. 2017 Jan 15;227:83-88. doi: 10.1016/j.ijcard.2016.11.072. Epub 2016 Nov 9.
6
Prognostic impact of baseline glucose levels in acute myocardial infarction complicated by cardiogenic shock—a substudy of the IABP-SHOCK II-trial [corrected].急性心肌梗死合并心原性休克患者基线血糖水平对预后的影响——IABP-SHOCK II 试验的亚研究[已更正]。
Clin Res Cardiol. 2018 Jun;107(6):517-523. doi: 10.1007/s00392-018-1213-7. Epub 2018 Feb 8.
7
Culprit lesion location and outcome in patients with cardiogenic shock complicating myocardial infarction: a substudy of the IABP-SHOCK II-trial.心肌梗死合并心源性休克患者的罪犯病变部位与预后:IABP-SHOCK II试验的一项子研究
Clin Res Cardiol. 2016 Dec;105(12):1030-1041. doi: 10.1007/s00392-016-1017-6. Epub 2016 Jul 4.
8
Osteoprotegerin in ST-elevation myocardial infarction: prognostic impact and association with markers of myocardial damage by magnetic resonance imaging.ST 段抬高型心肌梗死中的骨保护素:预后影响及与磁共振成像心肌损伤标志物的相关性。
Int J Cardiol. 2013 Sep 1;167(5):2134-9. doi: 10.1016/j.ijcard.2012.05.101. Epub 2012 Jun 15.
9
GLP-1 in patients with myocardial infarction complicated by cardiogenic shock-an IABP-SHOCK II-substudy.GLP-1 在心肌梗死后伴心原性休克患者中的应用:一项 IABP-SHOCK II 亚组研究。
Clin Res Cardiol. 2024 Aug;113(8):1211-1218. doi: 10.1007/s00392-023-02366-2. Epub 2024 Jan 3.
10
Impact of intra-aortic balloon pump support initiated before versus after primary percutaneous coronary intervention in patients with cardiogenic shock from acute myocardial infarction.主动脉内球囊反搏支持在急性心肌梗死后心原性休克患者中在直接经皮冠状动脉介入治疗之前与之后开始的影响。
Int J Cardiol. 2013 Oct 9;168(4):3758-63. doi: 10.1016/j.ijcard.2013.06.009. Epub 2013 Jul 3.

引用本文的文献

1
Current and novel biomarkers in cardiogenic shock.心源性休克中的当前及新型生物标志物
Eur J Heart Fail. 2025 Jan 17. doi: 10.1002/ejhf.3531.
2
The Role of Inflammation in the Pathogenesis of Cardiogenic Shock Secondary to Acute Myocardial Infarction: A Narrative Review.炎症在急性心肌梗死继发心源性休克发病机制中的作用:一项叙述性综述
Biomedicines. 2024 Sep 11;12(9):2073. doi: 10.3390/biomedicines12092073.
3
Growth differentiation factor-15 as a biomarker of coronary microvascular dysfunction in ST-segment elevation myocardial infarction.
生长分化因子-15作为ST段抬高型心肌梗死中冠状动脉微血管功能障碍的生物标志物。
Heliyon. 2024 Jul 30;10(15):e35476. doi: 10.1016/j.heliyon.2024.e35476. eCollection 2024 Aug 15.
4
Cardiogenic Shock: Focus on Non-Cardiac Biomarkers.心原性休克:关注非心脏生物标志物。
Curr Heart Fail Rep. 2024 Dec;21(6):604-614. doi: 10.1007/s11897-024-00676-8. Epub 2024 Jul 30.
5
Role of the Stress- and Inflammation-Induced Cytokine GDF-15 in Cardiovascular Diseases: From Basic Research to Clinical Relevance.应激和炎症诱导的细胞因子生长分化因子15在心血管疾病中的作用:从基础研究到临床相关性
Rev Cardiovasc Med. 2023 Mar 6;24(3):81. doi: 10.31083/j.rcm2403081. eCollection 2023 Mar.
6
Growth differentiation factor-15 predicts all-cause death and major adverse cardiovascular events in patients with coronary heart disease: a prospective cohort study.生长分化因子 15 可预测冠心病患者的全因死亡和主要不良心血管事件:一项前瞻性队列研究。
J Thromb Thrombolysis. 2024 Oct;57(7):1109-1121. doi: 10.1007/s11239-024-03019-5. Epub 2024 Jul 28.
7
Targeted proteomic profiling of cardiogenic shock in the cardiac intensive care unit.心脏重症监护病房心源性休克的靶向蛋白质组学分析。
Eur Heart J Acute Cardiovasc Care. 2024 Aug 28;13(8):624-628. doi: 10.1093/ehjacc/zuae068.
8
GLP-1 in patients with myocardial infarction complicated by cardiogenic shock-an IABP-SHOCK II-substudy.GLP-1 在心肌梗死后伴心原性休克患者中的应用:一项 IABP-SHOCK II 亚组研究。
Clin Res Cardiol. 2024 Aug;113(8):1211-1218. doi: 10.1007/s00392-023-02366-2. Epub 2024 Jan 3.
9
Extending the 'host response' paradigm from sepsis to cardiogenic shock: evidence, limitations and opportunities.将“宿主反应”范式从脓毒症扩展到心源性休克:证据、局限性和机会。
Crit Care. 2023 Nov 27;27(1):460. doi: 10.1186/s13054-023-04752-8.
10
Early Recognition and Risk Stratification in Cardiogenic Shock: Well Begun Is Half Done.心源性休克的早期识别与风险分层:良好的开端是成功的一半。
J Clin Med. 2023 Apr 1;12(7):2643. doi: 10.3390/jcm12072643.